In the Claims:

Please cancel claims 1-9 and amend claim 10 as follows:

- 1-9. (Cancelled)
- 10. (Currently Amended) A method of <u>treatingment eaneer by administering</u> by intravenous drip, a composition of claim 5 acute promyelocytic leukemia in humans comprising the steps of:
- (a) preparing an aqueous solution consisting of approximately 0.1% to 1.0% by weight arsenic trioxide and at least one pH-buffering agent selected from the group consisting of hydrochloric acid, alkali hydroxide, and carbonate solutions;
- (b) sterilizing said aqueous solution to form an injectably administrable acute promyelocytic leukemia treating composition; and
- (c) administering said composition as an intravenous drip to a human in need of treatment for acute promyelocytic leukemia.

Please add the following claims:

- 11. (New) The method of claim 10, wherein the at least one pH-buffering agent comprises hydrochloric acid and sodium hydroxide.
 - 12. (New) A method of treating leukemia in humans comprising the steps of:
- (a) preparing an aqueous solution consisting of approximately 0.1% to 1.0% by weight arsenic trioxide and at least one pH-buffering agent selected from the group consisting of hydrochloric acid, alkali hydroxide, and carbonate solutions;
- (b) sterilizing said aqueous solution to form an injectably administrable leukemia treating composition; and
- (c) administering said composition as an intravenous drip to a human in need of treatment for leukemia.
- 13. (New) The method of claim 12, wherein the at least one pH-buffering agent comprises hydrochloric acid and sodium hydroxide
- 14. (New) The method of claim 12, wherein the aqueous solution further consists of 0.8% by weight sodium chloride and 10% by weight glucose.

ATTORNEY DOCKET NO. WAX017-185360C

- 15. (New) The method of claim 12, wherein step (c) is repeated on a daily basis for approximately 2 to 4 weeks.
- 16 (New) The method of claim 12, further comprising, after the administering step, ceasing administration of the composition.
- 17. (New) The method of claim 16, wherein the administration and ceasing steps are repeated on a daily basis for approximately 2 to 4 weeks.